Peptides having ANF activity
    3.
    发明授权
    Peptides having ANF activity 失效
    具有ANF活性的肽

    公开(公告)号:US5091366A

    公开(公告)日:1992-02-25

    申请号:US534001

    申请日:1990-06-04

    IPC分类号: A61K38/00 C07K14/58

    CPC分类号: C07K14/58 A61K38/00

    摘要: Analogs of the 17-membered ring portion of ANF wherein the cysteine moiety is replaced with dipeptidyl moieties, specifically, Phe-Pro, NMP-Pro, Pro-Pro, Val-Pro, Lys-Pro, Ile-Pro, Arg-Pro, HAr-Pro, Dly-Pro, Arg-Pro, Lys-BAr, Arg-Pro, CyA-CyA, Cys-Cys, or with .alpha.-aminoheptanoic acid result in analogs of ANF having increased potencies and metabolic stability.

    摘要翻译: ANF的17-元环部分的类似物,其中半胱氨酸部分被二肽基部分,特别是Phe-Pro,NMP-Pro,Pro-Pro,Val-Pro,Lys-Pro,Ile-Pro,Arg-Pro, HAr-Pro,Dly-Pro,Arg-Pro,Lys-BAr,Arg-Pro,CyA-CyA,Cys-Cys或α-氨基庚酸导致ANF的类似物具有增加的效力和代谢稳定性。

    Fibrinogen receptor antagonists
    8.
    发明授权
    Fibrinogen receptor antagonists 失效
    纤维蛋白原受体拮抗剂

    公开(公告)号:US5340798A

    公开(公告)日:1994-08-23

    申请号:US961221

    申请日:1992-10-14

    摘要: The present invention comprises fibrinogen receptor antagonist compounds, compositions containing them and methods for using them to inhibit fibrinogen binding to blood platelets. Compounds of the invention have the following formula ##STR1## wherein Z is ##STR2## X is COOH, CH.sub.2 SH or SH; R.sup.1 is Y--R.sup.3, wherein R.sup.3 is alkyl and Y is amino, pyridinyl, pyrimidinyl or piperidinyl;R.sup.2 is H, alkyl, aryl, or arylalkyl; andR.sup.4 is alkyl, heteroalkyl, aryl or heteroaryl, wherein the aryl or heteroaryl group can be mono- or bi-cyclic.An exemplary compound of the invention is ##STR3##

    摘要翻译: 本发明包括纤维蛋白原受体拮抗剂化合物,含有它们的组合物和使用它们来抑制纤维蛋白原与血小板结合的方法。 本发明化合物具有下列结构式:其中Z为X,CO为COOH,CH 2 SH或SH; R1是Y-R3,其中R3是烷基,Y是氨基,吡啶基,嘧啶基或哌啶基; R2是H,烷基,芳基或芳基烷基; 并且R 4是烷基,杂烷基,芳基或杂芳基,其中芳基或杂芳基可以是单环或双环的。 本发明的示例性化合物是 V

    Bicyclic somatostatin analogs
    9.
    发明授权
    Bicyclic somatostatin analogs 失效
    双相生长抑素类似物

    公开(公告)号:US4191754A

    公开(公告)日:1980-03-04

    申请号:US16218

    申请日:1979-02-28

    摘要: Bicyclic somatostatin analogs and pharmaceutically acceptable non-toxic acid addition salts thereof are prepared by a combination of the solid phase method and the solution method. These analogs have the property of inhibiting the release of insulin, glucagon and growth hormone in humans and animals. The compounds are particularly useful in the treatment of diabetes. Due to the bicyclic structure, these analogs are resistant to enzymatic metabolism and have a longer duration of activity.

    摘要翻译: 双相生长抑素类似物及其药学上可接受的无毒酸加成盐通过固相法和溶液法的组合制备。 这些类似物具有抑制人和动物中胰岛素,胰高血糖素和生长激素释放的性质。 该化合物特别可用于治疗糖尿病。 由于双环结构,这些类似物对酶代谢具有抗性并且具有更长的活性持续时间。